Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

Cited In for PubMed (Select 9667259)

1.

BRCA1 Circos: a visualisation resource for functional analysis of missense variants.

Jhuraney A, Velkova A, Johnson RC, Kessing B, Carvalho RS, Whiley P, Spurdle AB, Vreeswijk MP, Caputo SM, Millot GA, Vega A, Coquelle N, Galli A, Eccles D, Blok MJ, Pal T, van der Luijt RB, Santamariña Pena M, Neuhausen SL, Donenberg T, Machackova E, Thomas S, Vallée M, Couch FJ, Tavtigian SV, Glover JN, Carvalho MA, Brody LC, Sharan SK, Monteiro AN; ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) Consortium.

J Med Genet. 2015 Apr;52(4):224-30. doi: 10.1136/jmedgenet-2014-102766. Epub 2015 Feb 2.

2.

Clinical and genetic characterization of basal cell carcinoma and breast cancer in a single patient.

Morelle A, Cericatto R, Krepischi AC, Ruiz IR.

Springerplus. 2014 Aug 22;3:454. doi: 10.1186/2193-1801-3-454. eCollection 2014.

3.

Completeness of pedigree and family cancer history for ovarian cancer patients.

Son Y, Lim MC, Seo SS, Kang S, Park SY.

J Gynecol Oncol. 2014 Oct;25(4):342-8. doi: 10.3802/jgo.2014.25.4.342. Epub 2014 Aug 5.

4.

Role of BRCA1 and BRCA2 gene mutations in epithelial ovarian cancer in Indian population: a pilot study.

Sharma S, Rajaram S, Sharma T, Goel N, Agarwal S, Banerjee BD.

Int J Biochem Mol Biol. 2014 May 15;5(1):1-10. eCollection 2014.

5.

Probing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1.

Carvalho RS, Abreu RB, Velkova A, Marsillac S, Rodarte RS, Suarez-Kurtz G, Iversen ES, Monteiro AN, Carvalho MA.

PLoS One. 2014 May 20;9(5):e97766. doi: 10.1371/journal.pone.0097766. eCollection 2014.

6.

Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins.

Ye Q, Chen L, Yin X, Liu YJ, Ji Q, Zhao E.

Pathol Oncol Res. 2014 Oct;20(4):931-8. doi: 10.1007/s12253-014-9776-8. Epub 2014 Apr 22.

7.

Frailty Models for Familial Risk with Application to Breast Cancer.

Gorfine M, Hsu L, Parmigiani G.

J Am Stat Assoc. 2013 Dec 1;108(504):1205-1215.

8.

An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population.

Mostowska A, Pawlik P, Sajdak S, Markowska J, Pawałowska M, Lianeri M, Jagodzinski PP.

Mol Diagn Ther. 2014 Feb;18(1):85-91.

9.

Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families.

Novaković S, Milatović M, Cerkovnik P, Stegel V, Krajc M, Hočevar M, Zgajnar J, Vakselj A.

Int J Oncol. 2012 Nov;41(5):1619-27. doi: 10.3892/ijo.2012.1595. Epub 2012 Aug 21.

10.

Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2.

Beristain E, Ibáñez B, Vergara I, Martínez-Bouzas C, Guerra I, Tejada MI.

J Community Genet. 2010 Jun;1(2):91-9. doi: 10.1007/s12687-010-0014-0. Epub 2010 Aug 9.

11.

Ethnic, racial and cultural identity and perceived benefits and barriers related to genetic testing for breast cancer among at-risk women of African descent in New York City.

Sussner KM, Edwards TA, Thompson HS, Jandorf L, Kwate NO, Forman A, Brown K, Kapil-Pair N, Bovbjerg DH, Schwartz MD, Valdimarsdottir HB.

Public Health Genomics. 2011;14(6):356-70. doi: 10.1159/000325263. Epub 2011 May 3.

12.

Do-it-yourself genetic testing.

Salzberg SL, Pertea M.

Genome Biol. 2010;11(10):404. doi: 10.1186/gb-2010-11-10-404. Epub 2010 Oct 7.

13.

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.

Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, Nord AS, Mandell JB, Swisher EM, King MC.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12629-33. doi: 10.1073/pnas.1007983107. Epub 2010 Jun 28.

14.

Pharmacogenetics and personal genomes.

Wagner MJ.

Per Med. 2009 Nov 1;6(6):643-652.

15.

Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers.

Caruso A, Vigna C, Marozzo B, Sega FM, Sperduti I, Cognetti F, Savarese A.

J Exp Clin Cancer Res. 2009 Dec 21;28:157. doi: 10.1186/1756-9966-28-157.

16.

Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection.

van Harssel JJ, van Roozendaal CE, Detisch Y, Brandão RD, Paulussen AD, Zeegers M, Blok MJ, Gómez García EB.

Fam Cancer. 2010 Jun;9(2):193-201. doi: 10.1007/s10689-009-9305-1.

17.

Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers.

Miolo G, Canzonieri V, De Giacomi C, Puppa LD, Dolcetti R, Lombardi D, Perin T, Scalone S, Veronesi A, Viel A.

BMC Cancer. 2009 Oct 10;9:360. doi: 10.1186/1471-2407-9-360.

18.

Diffusion of breast cancer risk assessment in primary care.

Guerra CE, Sherman M, Armstrong K.

J Am Board Fam Med. 2009 May-Jun;22(3):272-9. doi: 10.3122/jabfm.2009.03.080153.

19.

Age-dependent penetrance of different germline mutations in the BRCA1 gene.

Al-Mulla F, Bland JM, Serratt D, Miller J, Chu C, Taylor GT.

J Clin Pathol. 2009 Apr;62(4):350-6. doi: 10.1136/jcp.2008.062646.

20.

Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes.

O'Neill SC, Rini C, Goldsmith RE, Valdimarsdottir H, Cohen LH, Schwartz MD.

Psychooncology. 2009 Oct;18(10):1088-96. doi: 10.1002/pon.1467.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk